权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Temporospatial psychosine accumulation and targeted adeno-associated virus (AAV) gene therapy in canine Krabbe disease

犬克拉伯病的时空心理激素积累和靶向腺相关病毒（AAV）基因治疗

基本信息

批准号：
10413945
负责人：
Allison M Bradbury
金额：
$ 24.4万
依托单位：
RESEARCH INST NATIONWIDE CHILDREN'S HOSP
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-06-05 至 2024-05-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10413945
关键词：
2 year old Affect Age Animal Model Area Attenuated Biochemical Biodistribution Biology Brain Breeding Canis familiaris Capsid Cations Cells Cerebellum Cerebrospinal Fluid Cerebrum Cessation of life Childhood Clinical Clinical Trials Data Defect Demyelinations Dependovirus Development Disease Disease Progression Early Intervention Enzymes Faculty Funding Mechanisms Galactosylceramides Genes Globoid cell leukodystrophy Goals Hereditary Disease Human Impairment Infant Inherited Institution Insulin-Like Growth Factor II Intravenous Laboratories Life Lipids Location Longevity Lysosomes Mediating Mentors Methods Modeling Mutation Myelin Myelin Basic Proteins National Research Service Awards Nature Neurodegenerative Disorders Neurologic Neurologic Dysfunctions Oligodendroglia Pathogenicity Pathologic Pennsylvania Peripheral Nervous System Phase Positioning Attribute Postdoctoral Fellow Protocols documentation Psychosine Research Research Personnel Resources Schwann Cells Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization Spinal Cord Therapeutic Therapeutic Intervention Therapy trial Time Tissues Treatment Efficacy Universities adeno-associated viral vector base blood-brain barrier penetration canine model career development cell type cellular targeting clinical implementation clinically relevant cytotoxic effective therapy galactosylceramidase gene therapy human disease improved insight leukodystrophy lipidomics mass spectrometric imaging myelination neurotoxic novel pre-clinical promoter receptor skills tenure track therapeutic evaluation training opportunity

项目摘要

Project Summary/Abstract Globoid cell leukodystrophy (GLD), commonly referred to as Krabbe disease, is a debilitating and always fatal pediatric neurodegenerative disease caused by a mutation in the gene encoding for the hydrolytic lysosomal enzyme galactosylceramidase (GALC). Accumulation of cytotoxic psychosine, a target of GALC, results in loss of oligodendrocytes and Schwann cells and widespread central and peripheral nervous system demyelination. Neurologic dysfunction is apparent in the first year of life and death often occurs by two years of age. Notably, GLD is a naturally occurring hereditary disease in dogs for which a breeding colony was established; Dr. Bradbury and her mentors currently maintain this breeding colony. Disease progression in GLD dogs closely recapitulates clinical, pathological, and biochemical abnormalities of human disease. The predictable disease progression and lifespan (15.7 ± 4.8 weeks of age) allow for timely identification of pathological changes and evaluation of therapeutic interventions. Furthermore, the increased size and complexity of the canine brain are similar to that of an infant allowing for implementation of clinically relevant methods to evaluate disease progression and therapeutic strategies. The long-term goal is to conduct therapy trials in this valuable large animal model to inform pediatric clinical trials. However, preliminary adeno-associated virus (AAV) studies in the GLD dog have provided insights to critical limitations of current gene therapy protocols. The applicant believes that it is vital to further elucidate underlying pathogenic mechanisms hindering therapy in this particular model and subsequently consider more novel gene therapy approaches to treat this disease. Herein Dr. Bradbury will use the canine model of GLD to further define the neurotoxic effect of psychosine on canine oligodendrocytes and use these data to develop temporospatial targeting of GALC delivered via AAV vectors to treat disease in this naturally occurring animal model. In the K99 phase she will evaluate the effect of psychosine on canine oligodendrocyte maturation and how this impacts rescue by gene therapy. She will also determine the temporospatial accumulation of psychosine in the brain and spinal cord and how it relates to the timing of myelin maturation in the canine brain. In the R00 phase Dr. Bradbury will focus on developing strategies to improve GALC biodistribution and targeting of pyschosine. Advances in AAV biology over the past decade provide for more tailored therapeutic approaches by targeting specific tissues, cells, and receptors. The K99/R00 funding mechanism will provide a necessary transition from NRSA postdoctoral fellow to an independent investigator. In addition to gaining new laboratory skills, the applicant's career development will be enhanced by the expertise of an exceptional advisory/mentoring committee. Additionally, the University of Pennsylvania is a top tier research institution with unparalleled resources and ample educational and training opportunities. The outstanding mentoring, unmatched resources, and strong commitment from her department will strengthen Dr. Bradbury's candidacy for, and transition to, an independent tenure-track faculty position. !

项目总结/文摘